Genotypic resistance tests for the management of the HIV-infected pregnant patient in Africa.
Single witness: The current development of guidelines for antiretroviral therapy in resource-limited settings raised the issues of the possible use of drug resistance testing (DRT) in middle- and low-income countries, especially in the context of prevention of mother-to-child transmission (MTCT) programmes. Although resource limitation make it clear that DRT cannot be recommended as an essential part of clinical management of HIV-infected pregnant women in Africa, it is important to monitor the prevalence and incidence of drug resistance on a population basis as ART is scaled up worldwide and programmes for the prevention of MTCT will be implemented. Moreover, even in low-resource countries there are some special settings where DRT may be available for patient care and its use may be considered.
Giaquinto
Carlo
C
Dipartimento di Pediatria, Università di Padova, Italy.
D000349:Africa / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000592:standards* / Q000639:trends; D003906:Developing Countries; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D011256:Pregnancy Outcome; D018570:Risk Assessment; D016896:Treatment Outcome
D019380:Anti-HIV Agents